Cargando…

Intravenous immunoglobulin for the treatment of Kawasaki disease

BACKGROUND: Kawasaki disease (KD) is an acute systemic vasculitis (inflammation of the blood vessels) that mainly affects children. Symptoms include fever, chapped lips, strawberry tongue, red eyes (bulbar conjunctival injection), rash, redness, swollen hands and feet or skin peeling; and enlarged c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Broderick, Cathryn, Kobayashi, Shinobu, Suto, Maiko, Ito, Shuichi, Kobayashi, Tohru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875364/ https://www.ncbi.nlm.nih.gov/pubmed/36695415 http://dx.doi.org/10.1002/14651858.CD014884.pub2

Ejemplares similares

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?
por: Han, Ji Whan
Publicado: (2017)

Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
por: Yu, Hun-Ju, et al.
Publicado: (2021)

Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms
por: Nadig, Pallavi L., et al.
Publicado: (2023)

Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease
por: Park, Hyo Min, et al.
Publicado: (2013)

Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease
por: Song, Min Seob
Publicado: (2019)

Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin
por: Galeotti, Caroline, et al.
Publicado: (2010)

Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease
por: Li, Wei, et al.
Publicado: (2022)

Risk Factors for Failure of Initial Intravenous Immunoglobulin Treatment in Kawasaki Disease
por: Cha, Sungho, et al.
Publicado: (2008)

Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment
por: Ko, Tai-Ming, et al.
Publicado: (2018)

Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Ma, Yongmei, et al.
Publicado: (2022)

Prediction of Resistance to Standard Intravenous Immunoglobulin Therapy in Kawasaki Disease
por: Lee, Sang Min, et al.
Publicado: (2014)

Hemolysis From Intravenous Immunoglobulin in Obese Patients With Kawasaki Disease
por: Van Anh, Khanh-Van Y., et al.
Publicado: (2020)

Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease
por: Lu, Yaheng, et al.
Publicado: (2021)

Peripheric arterial aneurisyms and monocytosis in intravenous immunoglobulin treatment resistant Kawasaki disease
por: Baskin, E, et al.
Publicado: (2008)

Thrombospondin-2 predicts response to treatment with intravenous immunoglobulin in children with Kawasaki disease
por: Yang, Shuai, et al.
Publicado: (2018)

Exposures associated with the onset of Kawasaki disease in infancy from the Japan Environment and Children’s Study
por: Fukuda, Sayaka, et al.
Publicado: (2021)

Retracted: Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Healthcare Engineering, Journal of
Publicado: (2023)

Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease
por: Han, Ji Whan
Publicado: (2017)

Effectiveness of Medium-Dose Intravenous Immunoglobulin (1 g/kg) in the Treatment of Kawasaki Disease
por: Yeo, Joong-Seok, et al.
Publicado: (2010)

Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease
por: Baek, Jin-Young, et al.
Publicado: (2016)

Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea
por: Hur, Gyu, et al.
Publicado: (2018)

Comparison of the Laboratory Data Between Kawasaki Disease and Enterovirus After Intravenous Immunoglobulin Treatment
por: Lin, Li-Yan, et al.
Publicado: (2012)

Low-dose Methotrexate Therapy for Intravenous Immunoglobulin-resistant Kawasaki Disease
por: Lee, Taek Jin, et al.
Publicado: (2008)

Sonographic Gallbladder Abnormality Is Associated with Intravenous Immunoglobulin Resistance in Kawasaki Disease
por: Chen, Chih-Jen, et al.
Publicado: (2012)

Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease
por: Xie, Tian, et al.
Publicado: (2017)

Randomized trial of different initial intravenous immunoglobulin regimens in Kawasaki disease
por: He, Lan, et al.
Publicado: (2021)

Prediction of unresponsiveness to second intravenous immunoglobulin treatment in patients with Kawasaki disease refractory to initial treatment
por: Seo, Euri, et al.
Publicado: (2016)

Treatment Response in Kawasaki Disease Is Associated with Sialylation Levels of Endogenous but Not Therapeutic Intravenous Immunoglobulin G
por: Ogata, Shohei, et al.
Publicado: (2013)

FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease
por: Kuo, Ho-Chang, et al.
Publicado: (2015)

Intravenous immunoglobulin resistance in Kawasaki disease patients: prediction using clinical data
por: Lam, Jonathan Y., et al.
Publicado: (2023)

Parameters to Guide Retreatment After Initial Intravenous Immunoglobulin Therapy in Kawasaki Disease
por: Kim, Hyun Kwon, et al.
Publicado: (2011)

Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease
por: Kemmotsu, Yasushi, et al.
Publicado: (2011)

Predictive factors of resistance to intravenous immunoglobulin and coronary artery lesions in Kawasaki disease
por: Lee, Hye Young, et al.
Publicado: (2016)

Relationship between vitamin D levels and intravenous immunoglobulin resistance in Kawasaki disease
por: Jun, Jae Sung, et al.
Publicado: (2017)

White Blood Cell and Neutrophil Counts and Response to Intravenous Immunoglobulin in Kawasaki Disease
por: Muto, Taichiro, et al.
Publicado: (2019)

Late-onset and long-term systemic dyshidrotic eczema after intravenous immunoglobulin treatment for Kawasaki disease
por: Yokoyama, Koji, et al.
Publicado: (2019)

Impact of Early Treatment With High-Dose Intravenous Immunoglobulin on Incidence of Kawasaki Disease Complications in Iranian Children
por: Karimi Yazdi, Alireza, et al.
Publicado: (2021)

Bioinformatics identification of hub genes and signaling pathways regulated by intravenous immunoglobulin treatment in acute Kawasaki disease
por: Huang, Hongbiao, et al.
Publicado: (2021)

Comparative Effectiveness of Intravenous Immunoglobulin for Children with Kawasaki Disease: A Nationwide Cohort Study
por: Lin, Ming-Chih, et al.
Publicado: (2013)

Plasma Clusterin Concentrations May Predict Resistance to Intravenous Immunoglobulin in Patients with Kawasaki Disease
por: Ou-Yang, Mei-Chen, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_m6dj9q4p0ig01ch4b74pbq6oor